Author:
Sanlorenzo Martina,Choudhry Aditi,Vujic Igor,Posch Christian,Chong Kim,Johnston Katia,Meier Melissa,Osella-Abate Simona,Quaglino Pietro,Daud Adil,Algazi Alain,Rappersberger Klemens,Ortiz-Urda Susana
Reference26 articles.
1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011
2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomized controlled trial;Hauschild;Lancet,2012
3. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors;LoRusso;J Clin Oncol,2012
4. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012
5. MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: a non-randomized, open-label phase 2 study;Ascierto;Lancet Oncol,2013
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献